DelMar Pharmaceuticals, Inc. (DMPI)

Home » Stocks » DMPI

Aug 20, 2020 - Stock symbol was changed to KTRA

Stock Price: $1.34 USD 0.00 (0.00%)

Updated Aug 19, 2020 4:00 PM EDT

• Overview
• News
• Financials

Key Info

Market Cap	15.35M
Revenue (ttm)	n/a
Net Income (ttm)	-7.90M
Shares Out	11.45M
EPS (ttm)	-0.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	Aug 19, 2020
Last Price	$1.34
Previous Close	$1.34
Change ($)	0.00
Change (%)	0.00%
Day's Open	-
Day's Range	1.17 - 1.35
Day's Volume	0
52-Week Range	0.38 - 1.53

More Stats

Market Cap	15.35M
Enterprise Value	10.38M
Earnings Date (est)	n/a
Ex-Dividend Date	n/a
Shares Outstanding	11.45M
Float	11.25M
EPS (basic)	-1.42
EPS (diluted)	-0.95
FCF / Share	-0.63

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	211,710
Short Ratio	0.24
Short % of Float	1.88%
Beta	1.85

PE Ratio	n/a
Forward PE	n/a
P/FCF Ratio	n/a
PS Ratio	n/a
PB Ratio	11.02
Revenue	n/a
Operating Income	-8.28M
Net Income	-7.90M
Free Cash Flow	-7.16M

Net Cash	4.97M
Net Cash / Share	0.43
Gross Margin	n/a
Operating Margin	n/a
Profit Margin	n/a
FCF Margin	n/a
ROA	-136.86%
ROE	-316.72%
ROIC	n/a

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy	0
Overweight	0
Hold	0
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: n/a

Price Target

$3.00*

(123.88% upside)

Low

2.00

Current: $1.34

High

4.00

Target: 3.00

*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Income Statement | Balance Sheet | Cash Flow

Year	2019	2018	2017	2016	2015
Revenue	-	-	-	-	-
Operating Income	-8.40	-11.17	-8.32	-6.21	-4.72
Net Income	-8.05	-11.14	-8.08	-8.86	-4.35
Shares Outstanding	2.57	2.09	1.20	1.09	0.95
Earnings Per Share	-3.16	-5.42	-7.40	-8.30	-4.60
Operating Cash Flow	-6.33	-9.85	-8.02	-5.15	-3.85
Free Cash Flow	-6.33	-9.85	-8.02	-5.15	-3.85
Cash & Equivalents	3.72	5.97	6.59	6.16	1.75
Net Cash / Debt	3.72	5.97	6.59	6.16	1.75
Assets	4.04	7.07	7.91	6.36	2.58
Liabilities	2.07	1.64	1.33	1.50	3.40
Book Value	1.97	5.44	6.58	4.86	-0.82

Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name	DelMar Pharmaceuticals, Inc.
Country	United States
Employees	2
CEO	Saiid Zarrabian

Stock Information

Ticker Symbol	DMPI
Stock Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
Unique Identifier	NASDAQ: DMPI

Description

DelMar Pharmaceuticals, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California.